The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Introducing yttrium-90 radioembolization to atezolizumab and bevacizumab regimen for intermediate and advanced stage hepatocellular carcinoma: A preliminary report of safety and effectiveness.
 
Qian Yu
No Relationships to Disclose
 
Yating Wang
No Relationships to Disclose
 
Ethan Ungchusri
No Relationships to Disclose
 
Mikin Patel
No Relationships to Disclose
 
Anjana Pillai
No Relationships to Disclose
 
Thuong Van Ha
No Relationships to Disclose
 
Chih-Yi Liao
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Exelixis; Genentech; Histosonics; Incyte; Ipsen; Lexicon; Lilly; QED Therapeutics; TransThera Biosciences
Speakers' Bureau - AstraZeneca; Eisai; Exelixis; Incyte
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Exelixis; Incyte; Ipsen
 
Osman Ahmed
No Relationships to Disclose